TCR therapies are among the cancer immunotherapies that aim to activate the body’s defense system in such a way that it can recognize and destroy cancer cells. In this therapy, doctors remove T cells from the immune system from the patient, genetically modify them so that they recognize the cancer cells as hostile, and give them back to the patient.
Biontech and Medigene want to develop cancer immunotherapies together
